HC Wainwright Lowers Earnings Estimates for Alpha Cognition

Alpha Cognition Inc. (NASDAQ:ACOG) – Research analysts at HC Wainwright cut their Q1 2026 earnings estimates for Alpha Cognition in a research report issued to clients and investors on Wednesday, April 8th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.28) per share for the quarter, down from their prior estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.01) EPS and FY2027 earnings at ($0.35) EPS.

Alpha Cognition (NASDAQ:ACOG) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The business had revenue of $2.60 million during the quarter, compared to analyst estimates of $4.41 million. Alpha Cognition had a negative net margin of 202.23% and a negative return on equity of 55.71%.

Separately, Wall Street Zen cut shares of Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $18.00.

Alpha Cognition Stock Performance

Shares of ACOG stock opened at $6.03 on Friday. The stock has a market capitalization of $131.27 million, a P/E ratio of -5.20 and a beta of 2.51. The company has a 50 day moving average price of $5.67 and a 200 day moving average price of $6.07. Alpha Cognition has a fifty-two week low of $3.97 and a fifty-two week high of $11.54.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Green Alpha Advisors LLC acquired a new position in Alpha Cognition during the 4th quarter worth approximately $72,000. Geode Capital Management LLC purchased a new stake in shares of Alpha Cognition during the 2nd quarter worth approximately $112,000. Massar Capital Management LP purchased a new stake in shares of Alpha Cognition during the 2nd quarter worth approximately $116,000. Berkshire Asset Management LLC PA lifted its position in shares of Alpha Cognition by 50.7% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock worth $116,000 after buying an additional 6,000 shares during the last quarter. Finally, Zullo Investment Group Inc. purchased a new stake in shares of Alpha Cognition during the 3rd quarter worth approximately $127,000.

Alpha Cognition News Summary

Here are the key news stories impacting Alpha Cognition this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with an $18 price target, signaling confidence in longer‑term upside. MarketBeat: HC Wainwright research
• Positive Sentiment: The firm raised several forecasts (Q3 2026 from -$0.31 to -$0.29; Q4 2026 from -$0.25 to -$0.20; FY2026 from -$1.12 to -$1.09), indicating an expectation of narrowing losses versus prior projections. MarketBeat: HC Wainwright research
• Neutral Sentiment: HC Wainwright published a detailed set of quarterly estimates through FY2027 (examples: Q1 2026 -$0.28, Q2 2027 -$0.10, Q3 2027 -$0.04, Q4 2027 -$0.01, FY2027 -$0.35), providing a roadmap for expected losses narrowing toward late‑2027. This gives guidance but not immediate revenue catalysts. MarketBeat: HC Wainwright research
• Negative Sentiment: HC Wainwright lowered its Q1 2026 EPS estimate (from -$0.24 to -$0.28), signaling weaker near‑term results than previously expected — a negative for short‑term sentiment. MarketBeat: HC Wainwright research
• Negative Sentiment: Despite revisions that narrow losses, HC Wainwright still projects Alpha Cognition will be loss‑making through FY2027 (FY2027 EPS -$0.35), keeping execution risk and dilution concerns in play for investors. MarketBeat: HC Wainwright research

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.